Regenesis Biomedical develops and markets regenerative medicine products, primarily the Provant Therapy System, which uses pulsed radio frequency energy (PRFE) to reduce pain and edema in post-operative, superficial soft tissues. The company sells to acute care hospitals, long-term acute care hospitals, skilled nursing facilities and outpatient clinics. Led by President and CEO Virginia Rybski, Regenesis holds patents on its Provant system and actively markets the device. The company completed a Series C financing to support growth. Proceeds are intended to accelerate expansion of its sales team to broaden clinical adoption.

Total raised

$5M

Funding rounds

1

Latest round

Series C

Latest activity

Jun 2011